STOCK TITAN

[Form 3] NovaBay Pharmaceuticals, Inc. Initial Statement of Beneficial Ownership

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
3

NovaBay Pharmaceuticals (NBY): Initial insider ownership filed. Framework Ventures IV L.P. and affiliated entities jointly filed a Form 3 disclosing preferred equity positions tied to NovaBay common stock.

On October 9, 2025, Framework LP purchased 220,663 shares of Series D Non-Voting Convertible Preferred Stock, which is convertible into a maximum of 1,164,117 shares of common stock, and acquired rights and obligations to purchase 134,375 shares of Series E Non-Voting Convertible Preferred Stock.

Following stockholder approval of proposals 5 and 9 at the October 16, 2025 annual meeting, each share of Series D Preferred converts into 160 common shares at the holder’s option or within three business days of the meeting, and each share of Series E Preferred converts into 160 common shares at the holder’s option or within thirty business days. The filing indicates a Director relationship and was submitted jointly pursuant to a Joint Filing Agreement dated October 20, 2025.

NovaBay Pharmaceuticals (NBY): Proprietà insider iniziale registrata. Framework Ventures IV L.P. e entità affiliate hanno presentato congiuntamente un Modulo 3 che rende note posizioni di capitale privilegiate legate alle azioni ordinarie NovaBay.

Il 9 ottobre 2025 Framework LP ha acquistato 220.663 azioni di Series D Non-Voting Convertible Preferred Stock, convertibili in un massimo di 1.164.117 azioni ordinarie, e ha acquisito diritti e obblighi per l'acquisto di 134.375 azioni di Series E Non-Voting Convertible Preferred Stock.

Dopo l'approvazione da parte degli azionisti delle proposte 5 e 9 nell'assemblea annuale del 16 ottobre 2025, ogni azione di Series D Preferred si convertirà in 160 azioni ordinarie a scelta del detentore o entro tre giorni lavorativi dall'assemblea, e ogni azione di Series E Preferred si convertirà in 160 azioni ordinarie a scelta del detentore o entro trenta giorni lavorativi. La dichiarazione mostra una relazione di Direttore ed è stata presentata congiuntamente ai sensi di un Joint Filing Agreement datato 20 ottobre 2025.

NovaBay Pharmaceuticals (NBY): Participación interna inicial registrada. Framework Ventures IV L.P. y entidades afiliadas presentaron conjuntamente un Formulario 3 que disclose posiciones de capital preferente vinculadas a las acciones comunes de NovaBay.

El 9 de octubre de 2025, Framework LP compró 220,663 acciones de Series D Non-Voting Convertible Preferred Stock, que son convertibles en un máximo de 1,164,117 acciones de acciones ordinarias, y adquirió derechos y obligaciones para comprar 134,375 acciones de Series E Non-Voting Convertible Preferred Stock.

Tras la aprobación por parte de los accionistas de las propuestas 5 y 9 en la asamblea anual del 16 de octubre de 2025, cada acción de Series D Preferred se convertirá en 160 acciones comunes a elección del tenedor o dentro de tres días hábiles posteriores a la reunión, y cada acción de Series E Preferred se convertirá en 160 acciones comunes a elección del tenedor o dentro de treinta días hábiles. La presentación indica una relación de Director y se presentó conjuntamente conforme a un Joint Filing Agreement fechado el 20 de octubre de 2025.

NovaBay Pharmaceuticals (NBY): 내부 보유 초기 공시. Framework Ventures IV L.P. 및 관련 법인은 NovaBay 보통주에 연결된 우선지분 보유를 공개하는 Form 3을 공동으로 제출했습니다.

2025년 10월 9일, Framework LP는 Series D Non-Voting Convertible Preferred Stock를 220,663주 매입했고 이는 최대 1,164,117주의 보통주로 전환될 수 있으며, 134,375주의 Series E Non-Voting Convertible Preferred Stock를 매수할 권리와 의무를 취득했습니다.

2025년 10월 16일 연례주총에서 제안 5 및 제안 9에 대한 주주 승인 이후, Series D Preferred의 각 주당은 보유자가 선택 시 또는 주총 이후 영업일 3일 이내에 160주의 보통주로 전환되며, Series E Preferred의 각 주당은 보유자가 선택 시 또는 영업일 30일 이내에 160주의 보통주로 전환됩니다. 공시는 이사가 관계를 명시하고 2025년 10월 20일자 Joint Filing Agreement에 따라 공동 제출되었습니다.

NovaBay Pharmaceuticals (NBY) : Participation interne initiale déposée. Framework Ventures IV L.P. et des entités affiliées ont déposé conjointement un Formulaire 3 révélant des positions en actions privilégiées liées aux actions ordinaires de NovaBay.

Le 9 octobre 2025, Framework LP a acheté 220 663 actions de Series D Non-Voting Convertible Preferred Stock, convertibles en un maximum de 1 164 117 actions ordinaires, et a acquis des droits et obligations pour acheter 134 375 actions de Series E Non-Voting Convertible Preferred Stock.

Suite à l'approbation des actionnaires des propositions 5 et 9 lors de l'assemblée annuelle du 16 octobre 2025, chaque action de Series D Preferred se convertira en 160 actions ordinaires à l'option du titulaire ou dans les trois jours ouvrables suivant l'assemblée, et chaque action de Series E Preferred se convertira en 160 actions ordinaires à l'option du titulaire ou dans les trente jours ouvrables. Le dossier indique une relation de Directeur et a été soumis conjointement en vertu d'un Joint Filing Agreement daté du 20 octobre 2025.

NovaBay Pharmaceuticals (NBY): Erstinsiderbesitz gemeldet. Framework Ventures IV L.P. und verbundene Einheiten haben gemeinsam ein Form 3 eingereicht, das bevorzugte Eigenkapitalpositionen im Zusammenhang mit NovaBay Stammaktien offengelegt.

Am 9. Oktober 2025 kaufte Framework LP 220.663 Aktien Series D Non-Voting Convertible Preferred Stock, die in maximal 1.164.117 Stammaktien umwandelbar sind, und erwarb Rechte und Pflichten zum Erwerb von 134.375 Aktien Series E Non-Voting Convertible Preferred Stock.

Nach der Abstimmung der Aktionäre über die Vorschläge 5 und 9 auf der ordentlichen Hauptversammlung am 16. Oktober 2025 wandelt jede Aktie der Series D Preferred nach Wahl des Inhabers oder innerhalb von drei Geschäftstagen nach der Versammlung in 160 Stammaktien, und jede Aktie der Series E Preferred nach Wahl des Inhabers oder innerhalb von dreißig Geschäftstagen in 160 Stammaktien um. Die Einreichung weist eine Direktor-Beziehung aus und wurde gemäß einer Joint Filing Agreement vom 20. Oktober 2025 gemeinsam eingereicht.

NovaBay Pharmaceuticals (NBY): الملكية الداخلية الأولية مُسجَّلة. قدمت Framework Ventures IV L.P. والجهات التابعة لها معًا نموذج 3 يكشف عن مواقع حقوق أسهم أولوية مرتبطة بأسهم شركة NovaBay العادية.

في 9 أكتوبر 2025، اشترت Framework LP 220,663 سهماً من Series D Non-Voting Convertible Preferred Stock، والتي يمكن تحويلها إلى ما يصل إلى 1,164,117 سهماً من الأسهم العادية، وامتلكت حقوق والتزامات لشراء 134,375 سهماً من Series E Non-Voting Convertible Preferred Stock.

بعد موافقة المساهمين على المقترحات 5 و9 في اجتماع الجمعية العامة السنوي في 16 أكتوبر 2025، يتم تحويل كل سهم من Series D Preferred إلى 160 سهماً عادياً حسب اختيار الحامل أو خلال ثلاثة أيام عمل من الاجتماع، ويتم تحويل كل سهم من Series E Preferred إلى 160 سهماً عادياً حسب اختيار الحامل أو خلال ثلاثين يوماً من الاجتماع. تشير التسجيل إلى علاقة مدير وتم تقديمه بشكل مشترك وفقًا لاتفاق تقديم مشترك مؤرّخ 20 أكتوبر 2025.

NovaBay Pharmaceuticals (NBY): 初始内部持股已备案。 Framework Ventures IV L.P.及相关实体联合提交了 Form 3,披露与 NovaBay 普通股相关的优先股头寸。

在 2025 年 10 月 9 日,Framework LP 购买了 220,663 股 Series D 非投票可转换优先股,可转换为最多 1,164,117 股普通股,并获得购买 134,375 股 Series E 非投票可转换优先股的权利与义务。

在 2025 年 10 月 16 日年度股东大会通过第 5 及第 9 项议案后,Series D 优先股的每股可在持有人选择时或大会结束后三个工作日内转换为 160 股普通股,Series E 优先股的每股可在持有人选择时或三十个工作日内转换为 160 股普通股。此披露涉及董事关系,并于 2025 年 10 月 20 日的共同提交协议下联合提交。

Positive
  • None.
Negative
  • None.

NovaBay Pharmaceuticals (NBY): Proprietà insider iniziale registrata. Framework Ventures IV L.P. e entità affiliate hanno presentato congiuntamente un Modulo 3 che rende note posizioni di capitale privilegiate legate alle azioni ordinarie NovaBay.

Il 9 ottobre 2025 Framework LP ha acquistato 220.663 azioni di Series D Non-Voting Convertible Preferred Stock, convertibili in un massimo di 1.164.117 azioni ordinarie, e ha acquisito diritti e obblighi per l'acquisto di 134.375 azioni di Series E Non-Voting Convertible Preferred Stock.

Dopo l'approvazione da parte degli azionisti delle proposte 5 e 9 nell'assemblea annuale del 16 ottobre 2025, ogni azione di Series D Preferred si convertirà in 160 azioni ordinarie a scelta del detentore o entro tre giorni lavorativi dall'assemblea, e ogni azione di Series E Preferred si convertirà in 160 azioni ordinarie a scelta del detentore o entro trenta giorni lavorativi. La dichiarazione mostra una relazione di Direttore ed è stata presentata congiuntamente ai sensi di un Joint Filing Agreement datato 20 ottobre 2025.

NovaBay Pharmaceuticals (NBY): Participación interna inicial registrada. Framework Ventures IV L.P. y entidades afiliadas presentaron conjuntamente un Formulario 3 que disclose posiciones de capital preferente vinculadas a las acciones comunes de NovaBay.

El 9 de octubre de 2025, Framework LP compró 220,663 acciones de Series D Non-Voting Convertible Preferred Stock, que son convertibles en un máximo de 1,164,117 acciones de acciones ordinarias, y adquirió derechos y obligaciones para comprar 134,375 acciones de Series E Non-Voting Convertible Preferred Stock.

Tras la aprobación por parte de los accionistas de las propuestas 5 y 9 en la asamblea anual del 16 de octubre de 2025, cada acción de Series D Preferred se convertirá en 160 acciones comunes a elección del tenedor o dentro de tres días hábiles posteriores a la reunión, y cada acción de Series E Preferred se convertirá en 160 acciones comunes a elección del tenedor o dentro de treinta días hábiles. La presentación indica una relación de Director y se presentó conjuntamente conforme a un Joint Filing Agreement fechado el 20 de octubre de 2025.

NovaBay Pharmaceuticals (NBY): 내부 보유 초기 공시. Framework Ventures IV L.P. 및 관련 법인은 NovaBay 보통주에 연결된 우선지분 보유를 공개하는 Form 3을 공동으로 제출했습니다.

2025년 10월 9일, Framework LP는 Series D Non-Voting Convertible Preferred Stock를 220,663주 매입했고 이는 최대 1,164,117주의 보통주로 전환될 수 있으며, 134,375주의 Series E Non-Voting Convertible Preferred Stock를 매수할 권리와 의무를 취득했습니다.

2025년 10월 16일 연례주총에서 제안 5 및 제안 9에 대한 주주 승인 이후, Series D Preferred의 각 주당은 보유자가 선택 시 또는 주총 이후 영업일 3일 이내에 160주의 보통주로 전환되며, Series E Preferred의 각 주당은 보유자가 선택 시 또는 영업일 30일 이내에 160주의 보통주로 전환됩니다. 공시는 이사가 관계를 명시하고 2025년 10월 20일자 Joint Filing Agreement에 따라 공동 제출되었습니다.

NovaBay Pharmaceuticals (NBY) : Participation interne initiale déposée. Framework Ventures IV L.P. et des entités affiliées ont déposé conjointement un Formulaire 3 révélant des positions en actions privilégiées liées aux actions ordinaires de NovaBay.

Le 9 octobre 2025, Framework LP a acheté 220 663 actions de Series D Non-Voting Convertible Preferred Stock, convertibles en un maximum de 1 164 117 actions ordinaires, et a acquis des droits et obligations pour acheter 134 375 actions de Series E Non-Voting Convertible Preferred Stock.

Suite à l'approbation des actionnaires des propositions 5 et 9 lors de l'assemblée annuelle du 16 octobre 2025, chaque action de Series D Preferred se convertira en 160 actions ordinaires à l'option du titulaire ou dans les trois jours ouvrables suivant l'assemblée, et chaque action de Series E Preferred se convertira en 160 actions ordinaires à l'option du titulaire ou dans les trente jours ouvrables. Le dossier indique une relation de Directeur et a été soumis conjointement en vertu d'un Joint Filing Agreement daté du 20 octobre 2025.

NovaBay Pharmaceuticals (NBY): Erstinsiderbesitz gemeldet. Framework Ventures IV L.P. und verbundene Einheiten haben gemeinsam ein Form 3 eingereicht, das bevorzugte Eigenkapitalpositionen im Zusammenhang mit NovaBay Stammaktien offengelegt.

Am 9. Oktober 2025 kaufte Framework LP 220.663 Aktien Series D Non-Voting Convertible Preferred Stock, die in maximal 1.164.117 Stammaktien umwandelbar sind, und erwarb Rechte und Pflichten zum Erwerb von 134.375 Aktien Series E Non-Voting Convertible Preferred Stock.

Nach der Abstimmung der Aktionäre über die Vorschläge 5 und 9 auf der ordentlichen Hauptversammlung am 16. Oktober 2025 wandelt jede Aktie der Series D Preferred nach Wahl des Inhabers oder innerhalb von drei Geschäftstagen nach der Versammlung in 160 Stammaktien, und jede Aktie der Series E Preferred nach Wahl des Inhabers oder innerhalb von dreißig Geschäftstagen in 160 Stammaktien um. Die Einreichung weist eine Direktor-Beziehung aus und wurde gemäß einer Joint Filing Agreement vom 20. Oktober 2025 gemeinsam eingereicht.

SEC Form 3
FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0104
Estimated average burden
hours per response: 0.5
1. Name and Address of Reporting Person*
Framework Ventures IV L.P.

(Last) (First) (Middle)
600 MONTGOMERY STREET, FLOOR 42

(Street)
SAN FRANCISCO CA 94111

(City) (State) (Zip)
2. Date of Event Requiring Statement (Month/Day/Year)
10/09/2025
3. Issuer Name and Ticker or Trading Symbol
NovaBay Pharmaceuticals, Inc. [ NBY ]
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director X 10% Owner
Officer (give title below) Other (specify below)
5. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
Form filed by One Reporting Person
X Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
Table II - Derivative Securities Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year) 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
Date Exercisable Expiration Date Title Amount or Number of Shares
Series D Non-Voting Convertible Preferred Stock 10/16/2025 (2) Common Stock 1,164,117(1) $0.00(2) D(3)
1. Name and Address of Reporting Person*
Framework Ventures IV L.P.

(Last) (First) (Middle)
600 MONTGOMERY STREET, FLOOR 42

(Street)
SAN FRANCISCO CA 94111

(City) (State) (Zip)

Relationship of Reporting Person(s) to Issuer
Director X 10% Owner
Officer (give title below) Other (specify below)
1. Name and Address of Reporting Person*
Framework Ventures Management LLC

(Last) (First) (Middle)
600 MONTGOMERY STREET. FLOOR 42

(Street)
SAN FRANCISCO CA 94111

(City) (State) (Zip)

Relationship of Reporting Person(s) to Issuer
Director X 10% Owner
Officer (give title below) Other (specify below)
1. Name and Address of Reporting Person*
Framework Ventures IV GP LLC

(Last) (First) (Middle)
600 MONTGOMERY STREET, FLOOR 42

(Street)
SAN FRANCISCO CA 94111

(City) (State) (Zip)

Relationship of Reporting Person(s) to Issuer
Director X 10% Owner
Officer (give title below) Other (specify below)
1. Name and Address of Reporting Person*
Spencer Vance

(Last) (First) (Middle)
600 MONTGOMERY STREET, FLOOR 42

(Street)
SAN FRANCISCO CA 94111

(City) (State) (Zip)

Relationship of Reporting Person(s) to Issuer
Director X 10% Owner
Officer (give title below) Other (specify below)
Explanation of Responses:
1. On October 9, 2025, Framework Ventures IV L.P. ("Framework LP"), David Lazar (the "Seller") and certain other investors entered into a securities purchase agreement pursuant to which Framework LP purchased all of Seller's rights, title and interest in (i) 220,663 shares of the Issuer's Series D Non-Voting Convertible Preferred Stock, par value $0.01 per share (the "Series D Preferred Stock"), which is convertible into a maximum of 1,164,117 shares of the Issuer's Common Stock and (ii) the rights and obligation to purchase 134,375 shares of the Issuer's Series E Non-Voting Convertible Preferred Stock, par value $0.01 per share (the "Series E Preferred Stock").
2. Following stockholder approval of proposals 5 and 9 set forth in the Issuer's Definitive Proxy Statement on Schedule 14A, filed by the Issuer with the Securities and Exchange Commission on September 23, 2025, at the Issuer's annual meeting on October 16, 2025 (the "Meeting"), (i) each share of Series D Preferred Stock will automatically convert into 160 shares of common stock at the option of the holder or within three business days of the Meeting, and (ii) the Issuer will issue the Series E Preferred Stock, each share of which will automatically convert into 160 shares of common stock at the option of the holder or within thirty business days of the Meeting.
3. The reported securities may also be deemed to be beneficially owned by Framework Ventures GP IV LLC ("Framework GP"), Framework Ventures Management LLC ("Framework Management"), Vance Spencer ("Mr. Spencer") and Michael Ernest Anderson ("Mr. Anderson" and together with Framework GP, Framework Management, Mr. Spencer and Framework LP, the "Framework Entities"), each of which or whom disclaim beneficial ownership of these shares except to the extent of its or his pecuniary interest in such shares, if any. Framework GP is the general partner of Framework LP. Framework Management is the investment manager for Framework GP. Mr. Spencer and Mr. Anderson are members and the managers of Framework GP and the managing members of Framework Management.
Remarks:
Framework LP, Framework GP, Framework Management, Mr. Spencer and Mr. Anderson are jointly filing this Form 3 pursuant to the Joint Filing Agreement, dated October 20, 2025, filed with the Securities and Exchange Commission herewith (the "Joint Filing Agreement"). Exhibit List: Exhibit 99.1 - Joint Filing Agreement.
/s/ Michael Ernest Anderson 10/20/2025
/s/ Michael Ernest Anderson 10/20/2025
/s/ Michael Ernest Anderson 10/20/2025
/s/ Vance Spencer 10/20/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
Novabay Pharma

NYSE:NBY

NBY Rankings

NBY Latest News

NBY Latest SEC Filings

NBY Stock Data

6.97M
6.01M
0.02%
21.27%
31.61%
Biotechnology
Pharmaceutical Preparations
Link
United States
EMERYVILLE